First-pass extracted concept

cytokine-armored CAR-T cells

Candidate: concept label1 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

armored CAR-T cells

Extracted Explainers

What the tool is doing

This design class adds cytokine armoring to CAR-T cells as a next-generation strategy for solid tumors. The abstract gives IL-15 and IL-7/CCL19 as examples.

Source 1DOI PubMed

What problem it solves

It is presented as a way to address major barriers limiting CAR-T efficacy in solid tumors.

Source 1DOI PubMed

Alternatives

The abstract contrasts this class with logic-gated systems, localized delivery approaches, dominant-negative receptors, and BiTE co-expression.

Source 1DOI PubMed

Evidence Snippets

next-generation strategies-including cytokine-armored CAR-T cells (e.g., IL-15, IL-7/CCL19)

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1clinical efficacysupports2025Source 1DOI PubMed

Second- and third-generation CAR-T cells have shown restricted efficacy in clinical trials for solid tumors.

Quoted textsource-backed

Although second- and third-generation CAR-T cells have shown restricted efficacy in clinical trials

Claim 2limitationsupports2025Source 1DOI PubMed

CAR-T therapy in solid tumors faces major barriers including an immunosuppressive tumor microenvironment, tumor heterogeneity, and limited T cell persistence.

Quoted textsource-backed

their application in solid tumors remains a formidable challenge due to obstacles such as the immunosuppressive tumor microenvironment, tumor heterogeneity, and limited T cell persistence

Claim 3strategy promisesupports2025Source 1DOI PubMed

Cytokine-armored CAR-T cells, logic-gated systems, and localized delivery approaches demonstrate promising potential to overcome limitations of CAR-T therapy in solid tumors.

Quoted textsource-backed

next-generation strategies-including cytokine-armored CAR-T cells (e.g., IL-15, IL-7/CCL19), logic-gated systems, and localized delivery approaches-demonstrate promising potential to overcome these limitations